Sentence: Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .
Drug combination annotation:
[{'class': 'POS', 'spans': ['apalutamide', 'ADT'], 'is_context_needed': False}, {'class': 'POS', 'spans': [1, 2], 'is_context_needed': False}]